Air quality data helps to inform treatment plans and support ongoing management of respiratory conditions!
HAIFA, ISRAEL – January 27, 2021 – Leading pharmaceutical company Boehringer Ingelheim (BI) is now using BreezoMeter’s accurate, hyperlocal, environmental data to help provide greater value and more meaningful engagements with physicians and to better forecast patient environmental triggers.
Armed with BreezoMeter’s real-time and historical data, BI representatives can now help visualize and forecast how pollution and pollen can negatively impact patients’ symptoms. For example, in a particularly pollen-heavy season, BI respiratory business specialists can show physicians historical and current data in order to raise awareness of when environmental triggers may further exacerbate a patient’s condition.
For more than a century, as a family-owned company, BI has been a leader in the pharmaceutical field and leverages digital opportunities to maximize the value of therapies for patients and healthcare systems. Furthermore, they’ve always understood the critical role the pharma-physician relationship plays in improving patient care, and have prioritized a patient centric culture, including a holistic view of a patient’s health. This includes understanding environmental factors that impact chronic conditions — something that’s especially critical for respiratory disease sufferers because hyperlocal environmental conditions can exacerbate life-threatening symptoms.
“At Boehringer Ingelheim, we complement our commitment to developing innovative therapies by developing innovative digital solutions with the goal of supporting healthcare providers in managing chronic conditions,” said Jim Boushie, Executive Director, Business Transformation at Boehringer Ingelheim. “To improve respiratory health and treatment plans, we utilize BreezoMeter’s data to help expose the effects of high pollution and pollen. Their air quality analytics empower our teams and will continue to inform how we collaborate with physicians to improve patient outcomes.”
BreezoMeter uses multiple data sources and sophisticated modelling, and continuously tests for accuracy and reliability to deliver personalized, timely, and actionable environmental insights. With an understanding of how air quality and pollen can exacerbate symptoms of asthma, COPD, and other healthcare conditions, providers can direct patients how to better control their health.
“We mirror Boehringer Ingelheim’s mission to empower physicians and improve patient health with more informed healthcare decision making,” said Ran Korber, CEO at BreezoMeter. “When it comes to the health of patients suffering from chronic respiratory disorders, understanding the effects of environmental exposure before it happens can mean the difference between prevention and exacerbation, symptom-free days and hospitalization.”
Further industry uses of the data may include offering air quality data to physicians on an ongoing basis and/or engaging patients directly. For example, connected apps could send local air quality alerts to patients with recommendations to address symptom management. This pharma-physician-patient collaboration is the future of healthcare.
For a deeper dive into how healthcare and pharma companies like Boehringer Ingelheim benefit from BreezoMeter’s air quality insights, download our eBook: How to Improve Patient Care with Environmental Insights.
BreezoMeter is the leading provider of street-level and real-time air quality information, including air pollution, pollen and active fires data. Their free Android and iOS apps help individuals protect themselves from harmful air exposure. Their APIs enable businesses to increase sales & product engagement. BreezoMeter is already integrated by leading brands across healthcare, smart home, automotive, and cosmetic industries: www.breezometer.com